Tag Archives: canada

Hot Investor Mandate: Hong Kong PE Firm Seeks to Invest Up to $10 M in Clinically Validated Medical Device and Diagnostics Products with China Angle

12 Jul

A PE firm that is headquartered in Hong Kong with additional offices throughout China currently manages over US$4 billion in assets and invests across several industry sectors including healthcare. The firm is interested in pre-growth and growth stage companies. Typical investment size ranges from US$5-10 million in Series A rounds. The firm seeks to lead but is open to syndicating with co-investors. The firm is now looking for opportunities in China, the US, and Canada.

Within healthcare, the firm focuses on medical devices and diagnostic technologies that have a China angle. The firm prefers products that have achieved clinical validation with proven advantages. The firm is also interested in clinical-stage biopharmaceutical opportunities as well as health information technology. The firm is opportunistic in terms of indication areas but is less interested in orphan diseases.

The firm is looking for experienced management teams with track record of success. The firm typically requests board representation in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Canada-Based VC Partnered with China I-Bank to Invest Up to $10M or More in Life Science Companies in North America

3 May

A venture capital firm based in Canada is making investments out of its first fund which closed at $500M. The fund was jointly established with a leading Chinese investment bank. The firm usually makes initial investments in the range of $5M-$10M with additional capital reserved for follow-on investments, but is capable of making smaller or larger investments. The firm primarily makes straight equity investments, but may consider convertible notes for smaller/earlier rounds. On occasion, public companies may be considered for investment. The firm is open to opportunities globally and will lead rounds as well as co-invest in a syndicate. The firm has no set number of investments it makes per year, but is a relatively nimble firm and able to act quickly when an opportunity presents itself.

The firm’s focus is in health sciences, including therapeutics, devices, diagnostics and health IT. Generally, the firm focuses on assets with clinical data and will invest in up unto Ph. III. The firm will evaluate pre-clinical assets pending there is a strong scientific rationale, and tends to prioritize platform technologies for early-stage assets. As for medical device companies, the firm prefers to see products with clinical data.

The firm prefers to work with experienced management teams, but will consider first time entrepreneurs as well. The firm typically seeks a board seat along with investment and in addition to capital, seeks to add value through developmental, infrastructure and expertise support, as needed, through the firm’s global network. The firm’s approach is to establish long-term relationships with target companies, with a view to enable and strengthen management to realize the full potential and value of the technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Canada-Based Investment Group Provides Seed Funding to Medtech, Cleantech, and IT Sectors Across North America, With Canadian Focus

22 Mar

A venture capital fund, angel group, and registered exempt market dealer based in Toronto, Ontario is affiliated with early stage venture funds, including their accelerator fund I and II as well as an angel group. The firm usually acts a lead investor in rounds of up to $2M, with between $300K – $750K coming from the first-mentioned fund, and with additional capital usually coming from the angel group or other family offices or institutional investment partners. The firm has also participated, and will continue to participate, in larger syndicated investment rounds. The firm prefers to lead priced equity rounds and does not usually make investments in uncapped convertible debt or SAFEs (Simple Agreements for Future Equity).

Annually, the firm works with, and makes investments in, 8 to 12 early stage (Seed and Series A) companies in the IT, CleanTech and MedTech sectors. In the MedTech sector, the firm typically does not invest in products with a complex regulatory pathway. The firm is also interested in platform technologies and R&D service/tools companies. Historic MedTech investments include investments in (i) a company which has developed an imaging agent that illuminates tumors both at the surgery planning phase and inside the operating room, (ii) a company that manufactures the world’s only natural, non-toxic, mono-disperse nano particle extracted from sweet corn which has applications in the personal care/cosmetics, nutraceutical and biomedical spaces; and (iii) a company that has a proprietary in silico software platform that maps interactions of drug compounds against the human proteome to identify drug efficacy, side effects and toxicity risks.

The firm is focused on Canadian companies, but will also evaluate U.S.-based and international companies if there is a potential investment fit. The firm’s principals have significant technology, financial and legal experience. The firm’s ideal investment candidate is a company that will benefit from and can leverage this experience and network and to which the firm can provide additional long-term value beyond its cash investment. The firm tries to avoid taking on technology risk but will take on some commercialization risk and prefers entrepreneurs that have had at least one ‘win’ (or event better, at least one ‘loss’)

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: